Corporate ActionJul 24, 2026, 05:06 PM
Matinas BioPharma's ATM Sales Agreement Terminated by BTIG
AI Summary
Matinas BioPharma Holdings, Inc. announced the termination of its At-The-Market Sales Agreement with BTIG, LLC. BTIG notified the company of the immediate termination on July 23, 2026, in accordance with the agreement's terms. The original agreement, established in July 2020, allowed Matinas BioPharma to offer and sell up to $50 million of its common stock through BTIG. The company will not incur any termination penalties or related expenses.
Key Highlights
- BTIG, LLC terminated the At-The-Market Sales Agreement with Matinas BioPharma Holdings, Inc.
- The termination of the Sales Agreement is effective immediately.
- Matinas BioPharma is not subject to any termination penalties or expenses.
- The original agreement allowed the company to sell up to $50,000,000 in common stock.
- The Sales Agreement was initially entered into on July 2, 2020.
Price Impact
More from MTNB